Rachael Galvin, DO, MPH, on Understanding Barriers to Early-Phase Clinical Trial Enrollment

November 13, 2020
Hannah Slater
Hannah Slater

Research published by Galvin, et al. in the journal ONCOLOGY® demonstrated the necessity to understand why eligible patients with pancreatic adenocarcinoma elect not to participate in early-phase clinical trials.

A study published in the journal ONCOLOGY® demonstrated the necessity to understand why eligible patients with pancreatic adenocarcinoma elect not to participate in early-phase clinical trials.

According to the researchers, this information could provide insight into the patient experience and also help identify misconceptions and areas for improvement in education and the clinical trial enrollment process.

“Further characterization of barriers to clinical trial enrollment in pancreatic cancer patients could be used to develop interventions aimed at addressing these perceived barriers specifically,” the authors wrote. “Tailored interventions and further research in improving clinical trial enrollment are critical to making advances in treating this aggressive malignancy.”

In an interview with CancerNetwork®, Rachael Galvin, DO, MPH, of the department of Surgery at the Swedish Medical Center, discussed the study further and what this research could lend to those who design clinical trials for this patient population.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Reference:

Galvin R, Chung C, Achenbach A, Dziadkowiec O, Sen S. Barriers to Clinical Trial Enrollment in Patients With Pancreatic Adenocarcinoma Eligible for Early-Phase Clinical Trials. ONCOLOGY. https://www.cancernetwork.com/view/barriers-to-clinical-trial-enrollment-in-patients-with-pancreatic-adenocarcinoma-eligible-for-early-phase-clinical-trials